Clinical Trial Design for Medical Devices: Where Most Programs Go Wrong

← Back to All Insights

Medical device clinical trials are not small-molecule pharmaceutical trials. The endpoints, the comparators, the enrollment dynamics, and the operational constraints all differ. Device companies that hire trial leadership from pharmaceutical backgrounds consistently encounter the same set of design failures—failures that traditional clinical operations diligence rarely surfaces.

Device trials succeed or fail at the design stage. Operational execution can rescue a well-designed trial; it cannot rescue a poorly-designed one.

Endpoint Selection: Surrogate vs Clinical

Device pivotal trials often default to surrogate endpoints because clinical endpoints require longer follow-up and larger sample sizes. FDA increasingly demands clinical endpoints—or at minimum surrogate endpoints with established clinical validity. Sponsors who select endpoints based on what is achievable rather than what is clinically meaningful frequently face FDA Additional Information requests that add 12-18 months.

Comparator Selection

Active comparator selection is more consequential for device trials than for drug trials. The comparator defines the regulatory pathway (510(k) substantial equivalence requires a specific predicate; PMA non-inferiority requires a clinically appropriate active comparator). Mismatched comparators are one of the most common pivotal trial design errors.

Sample Size for Devices

Device trial sample sizes are typically smaller than pharmaceutical trials but should not be undersized. The 50-100 patient pivotal trial that worked for a Class II device in 2010 frequently does not work for the same device in 2025—FDA expectations have evolved. Sample size determinations based on outdated statistical assumptions are a common 510(k) and PMA rejection cause.

Multi-Site Enrollment Dynamics

Device trials enroll differently than drug trials. Physicians who participate need procedural training, often device-specific. Site startup is slower. Enrollment per site per month is often lower than pharmaceutical sponsors expect. Realistic enrollment modeling—built from device-specific historical data, not pharmaceutical analogs—is essential for credible timeline planning.

Operator Variability

Device performance frequently depends on operator skill. Trials that do not account for operator variability—through training requirements, certification protocols, or stratified analysis by operator experience—produce results that may not generalize to post-market use. FDA labeling decisions increasingly reflect operator-experience considerations.

Adaptive Designs and Pre-Submission Strategy

Modern device trials increasingly use adaptive designs to manage enrollment risk and improve evidence efficiency. The FDA Adaptive Designs guidance encourages adaptive approaches when properly pre-specified. Pre-Submission meetings (Q-Subs) are essential for validating adaptive design strategies before pivotal trial enrollment begins.

Medical device clinical trial design is its own discipline. Sponsors who treat it as a pharmaceutical exercise consistently encounter avoidable problems. Investors and acquirers should examine clinical trial design quality independently—the difference between a well-designed pivotal trial and a poorly-designed one frequently determines whether a device program succeeds or fails.